Study Graphic

You may be eligible if you:

  • are a healthy male or female (unable to bear children) 18-55 years of age
  • are able to meet all eligibility criteria
  • are able to comply with all study visits

Study Number: C4041001

Be compensated for your time: up to $1475.00

The Pfizer New Haven Clinical Research Unit is conducting a study of a new investigational drug being studied to treat people with pulmonary (lung) arterial hypertension (PAH). An “investigational drug” is a drug that has not been approved to treat disease. PAH is a disease that affects the arteries of the lungs, making them smaller and less able to carry blood. This causes the heart to work harder to pump blood through the lungs which causes high blood pressure (hypertension) on the right side of the heart. This is different from “typical” high blood pressure (as measured, for example, in your arm) which comes from increased pressures in the left side of the heart. This research study will be the first time the study drug will be given to people. Study drug and placebo will be given as a suspension (liquid), which you will drink or as 1 or more tablets that you will swallow, depending on which part of the study you are accepted into.

The study has 2 parts (Part A and Part B).

This study involves:

You will be in this study up to about 36 days. This does not include the time between screening and dosing, which can be up to 28 days.

This study involves:

  • 1 dosing period
  • 3 overnight stays
  • 1 follow-up visit to the clinic (about 7-10 days after the dose)
  • 1 follow-up phone call (about 28-35 days after the dose)

Up to approximately 80 healthy male and female participants will be in part A of the study, and up to approximately 18 healthy male and female participants will be in part B of the study. Females must not be able to have children.

Please review the informed consent document: C4041001 ICD v 12 Nov 2019